Practical recommendations for measuring rates of visual field change in glaucoma

British Journal of Ophthalmology

Volumn 92, Issue 4, 2008, Pages 569-573

  Chauhan, B C ^a   Garway Heath, D F ^b   Goni F J ^c   Rossetti, L ^d   Bengtsson, B ^e   Viswanathan, A C ^b   Heijl, A ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c Barcelona Glaucoma Centre   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATARACT; COMPUTER PROGRAM; GLAUCOMA; HUMAN; PERIMETRY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; STATISTICAL MODEL; VISUAL FIELD; VISUAL FIELD DEFECT;

EID: 41849110562     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.135012     Document Type: Review

References (58)

1. Gutierrez P, Wilson MR, Johnson C, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997;115:777-84.
2. Parrish RK 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115:1447-55.
3. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, et al. Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998;105:561-6.
4. Jampel HD, Friedman DS, Quigley H, et al. Correlation of the binocular visual field with patient assessment of vision. Invest Ophthalmol Vis Sci 2002;43:1059-67.
5. Nelson P, Aspinall P, Papasouliotis O, et al. Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003;12:139-50.
6. Hyman LG, Komaroff E, Heijl A, et al. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology 2005;112:1505-13.
7. The Advanced Glaucoma Intervention Study (AGIS). 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 1994;15:299-325.
8. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
9. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999;117:573-83.
10. Leske MC, Heijl A, Hyman L, et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology 1999;106:2144-53.
11. The Canadian Glaucoma Study Group. Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Can J Ophthalmol 2006;41:566-75.
12. Musch DC, Lichter PR, Guire KE, et al. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106:653- 62.
13. Hertzog LH, Albrecht KG, LaBree L, et al. Glaucoma care and conformance with preferred practice patterns. Examination of the private, community-based ophthalmologist. Ophthalmology 1996;103:1009-13.
14. Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 2005;112:1500-4.
15. Kwon YH, Kim CS, Zimmerman MB, et al. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 2001;132:47-56.
16. Eid TM, Spaeth GL, Bitterman A, et al. Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years. Ophthalmology 2003;110:900-7.
17. Zahari M, Mukesh BN, Rait JL, et al. Progression of visual field loss in open angle glaucoma in the Melbourne Visual Impairment Project. Clinical & experimental ophthalmology 2006;34:20-6.
18. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105: 2099-104.
19. Oliver JE, Hattenhauer MG, Herman D, et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol 2002;133:764-72.
20. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003;110:726-33.
21. Forsman E, Kivela T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 2007;16:313-9.
22. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology 2001;108:247-53.
23. Artes PH, Nicolela MT, LeBlanc RP, et al. Visual field progression in glaucoma: total versus pattern deviation analyses. Invest Ophthalmol Vis Sci 2005;46:4600-6.
24. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 1996;37:1419-28.
25. Shigeeda T, Tomidokoro A, Araie M, et al. Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology 2002;109:766-70.
26. Artes PH, Chauhan BC. Longitudinal changes in the visual field and optic disc in glaucoma. Prog Retin Eye Res 2005;24:333-54.
27. Bengtsson B, Lindgren A, Heijl A, et al. Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand 1997;75:184-8.
28. Heijl A, Lindgren G, Lindgren A, et al. Extended empirical statistical package for evaluation of single and multiple fields: Statpac 2. In: Mills RP, Heijl A, eds. Perimetry update 1990/1. New York: Kugler & Ghedini, 1991:303-15.
29. Viswanathan AC, Fitzke FW, Hitchings RA. Early detection of visual field progression in glaucoma: a comparison of PROGRESSOR and STATPAC 2. Br J Ophthalmol 1997;81:1037-42.
30. Weber J. Atlas der computerperimetrie. Berlin: Springer, 1993.
31. Quigley HA, Addicks EM, Green WR, Optic nerve damage in human glaucoma. III, Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol 1982;100:135-46.
32. Kerrigan-Baumrind LA, Quigley HA, Pease ME, et al. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 2000;41:741-8.
33. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989;107:453-64.
34. Garway-Heath DF, Caprioli J, Fitzke FW, et al. Scaling the hill of vision: the physiological relationship between light sensitivity and ganglion cell numbers. Invest Ophthalmol Vis Sci 2000;41:1774-82.
35. Ford BA, Artes PH, McCormick TA, et al. Comparison of data analysis tools for detection of glaucoma with the Heidelberg Retina Tomograph. Ophthalmology 2003;110:1145-50.
36. Medeiros FA, Zangwill LM, Bowd C, et al. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. Ach Ophthalmol 2004;122:827-37.
37. Zangwill LM, Bowd C, Berry CC, et al. Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph. Arch Ophthalmol 2001;119:985-93.
38. Wollstein G, Garway-Heath DF, Fontana L, et al. Identifying early glaucomatous changes. Comparison between expert clinical assessment of optic disc photographs and confocal scanning ophthalmoscopy. Ophthalmology 2000;107:2272-7.
39. Badala F, Nouri-Mahdavi K, Raoof DA, et al. Optic disk and nerve fiber layer imaging to detect glaucoma. Am J Ophthalmol 2007;144:724-32.
40. Haymes SA, Leblanc RP, Nicolela MT, et al. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 2007;48:1149-55.
41. McGwin G Jr, Owsley C, Ball K. Identifying crash involvement among older drivers: agreement between self-report and state records. Accident: analysis and prevention 1998;30:781-91.
42. Szlyk JP, Mahler CL, Seiple W, et al. Driving performance of glaucoma patients correlates with peripheral visual field loss. J Glaucoma 2005;14:145-50.
43. Johnson CA, Keltner JL, Cello KE, et al. Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology 2002;109:432-7.
44. Johnson CA, Nelson-Quigg JM. A prospective three-year study of response properties of normal subjects and patients during automated perimetry. Ophthalmology 1993;100:269-74.
45. Stewart WC, Rogers GM, Crinkley CM, et al. Effect of cataract extraction on automated fields in chronic open-angle glaucoma. Arch Ophthalmol 1995;113:875-9.
46. Carrillo MM, Artes PH, Nicolela MT, et al. Effect of cataract extraction on the visual fields of patients with glaucoma. Arch Ophthalmol 2005;123:929-32.
47. Smith SD, Katz J, Quigley HA. Effect of cataract extraction on the results of automated perimetry in glaucoma. Arch Ophthalmol 1997;115:1515-9.
48. Guthauser U, Flammer J. Quantifying visual field damage caused by cataract. Am J Ophthalmol 1988;106:480-4.
49. Heijl A, Lindgren G, Olsson J. A package for the statistical analysis of visual fields. Doc Ophthalmol Proc Ser 1987;49:153-68.
50. Heijl A, Leske MC, Bengtsson B, et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 2003;81:286-93.
51. Vesti E, Johnson CA, Chauhan BC. Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci 2003;44:3873-9.
52. Demirel S, Johnson CA. Incidence and prevalence of short wavelength automated perimetry deficits in ocular hypertensive patients. Am J Ophthalmol 2001;131:709-15.
53. Haymes SA, Hutchison DM, McCormick TA, et al. Glaucomatous visual field progression with frequency-doubling technology and standard automated perimetry in a longitudinal prospective study. Invest Ophthalmol Vis Sci 2005;46:547-54.
54. Strouthidis NG, Vinciotti V, Tucker AJ, et al. Structure and function in glaucoma: The relationship between a functional visual field map and an anatomic retinal map. Invest Ophthalmol Vis Sci 2006;47:5356-62.
55. Owen VM, Strouthidis NG, Garway-Heath DF, et al. Measurement variability in Heidelberg Retina Tomograph imaging of neuroretinal rim area. Invest Ophthalmol Vis Sci 2006;47:5322-30.
56. Jampel HD, Vitale S, Ding Y, et al. Test-retest variability in structural and functional parameters of glaucoma damage in the glaucoma imaging longitudinal study. J Glaucoma 2006;15:152-7.
57. Chauhan BC, LeBlanc RP, McCormick TA, et al. Test-retest variability of topographic measurements with confocal scanning laser tomography in patients with glaucoma and control subjects. Am J Ophthalmol 1994;118:9-15.
58. Brigatti L, Weitzman M, Caprioli J. Regional test-retest variability of confocal scanning laser tomography. Am J Ophthalmol 1995;120:433-40.